Recent RPTX News
- DEBIOPHARM ET REPARE THERAPEUTICS ANNONCENT LE TRAITEMENT D’UN PREMIER PATIENT DANS LE CADRE DE L’ÉTUDE DE PHASE 1/1B MYTHIC ÉVALUANT LA COMBINATION D’INHIBITEURS WEE1 ET PKMYT1 GÉNÉRANT UNE LÉTHALITÉ SYNTHÉTIQUE • Business Wire • 04/30/2024 11:05:00 AM
- Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition • Business Wire • 04/30/2024 11:05:00 AM
- Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition • Business Wire • 04/30/2024 11:05:00 AM
- Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors • Business Wire • 04/26/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:15:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 02:06:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 02:02:38 AM
- Repare Therapeutics to Participate in Two Upcoming Investor Conferences • Business Wire • 02/29/2024 12:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/28/2024 09:09:45 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:10:15 PM
- Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/28/2024 12:05:00 PM
- Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 • Business Wire • 02/15/2024 12:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 02:02:34 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:54:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:48:00 PM
- Repare Therapeutics to Regain Global Rights to Camonsertib • Business Wire • 02/12/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 07:29:21 PM
- Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment • Business Wire • 01/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:05:53 PM
- Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones • Business Wire • 01/08/2024 12:00:00 PM
- Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer • Business Wire • 01/04/2024 09:05:00 PM
- Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans • Business Wire • 12/29/2023 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 09:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 12:20:29 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM